On February 2, CSPC Pharmaceutical Group (1093.HK) announced that its clovidipine emulsion injection (50ml:25mg, 100ml:50mg) (hereinafter referred to as "the product") has obtained a drug registration certificate issued by the National Medical Products Administration of the People's Republic of China.This product is a dihydropyridine calcium channel blocker, a rapid-acting intravenous antihypertensive drug, suitable for treating hypertensive patients who are unsuitable for oral medication or whose oral medication is not expected to be effective. Compared with commonly used clinical drugs, this product has the following significant advantages: faster onset of action, enabling rapid, real-time, and precise blood pressure control; more suitable for patients with abnormal liver and kidney function, requiring no dosage adjustment during treatment; and no dilution or preparation required, significantly benefiting individuals at risk of fluid overload.
The approval of this product will further enrich the Group's product pipeline in the field of cardiovascular and cerebrovascular disease treatment, enhance the Group's competitiveness in this field, and is expected to fill the clinical demand gap for drugs for hypertensive emergencies.

https://mp.weixin.qq.com/s/ABGDpuM9p2kqzTDcLp0blA